Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet et al by Ramiro, S. et al.
Response to ‘The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic 
Arthritis clinical trials and longitudinal observational studies´ 
 
Sofia Ramiro, Josef S. Smolen, Robert Landewé, Désirée van der Heijde, Laure Gossec 
 
Sofia Ramiro, MD, PhD, Department of Rheumatology, Leiden University Medical Center, 
Leiden, the Netherlands. sofiaramiro@gmail.com  
 
Josef S. Smolen, MD, Division of Rheumatology, Department of Medicine 3, Medical 
University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria. 
josef.smolen@wienkav.at 
 
Robert Landewé, MD, PhD, Department of Clinical Immunology & Rheumatology, 
Amsterdam Rheumatology Center, Amsterdam and Zuyderland Hospital, Heerlen, The 
Netherlands. landewe@rlandewe.nl 
 
Désirée van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical 
Centre, Leiden, The Netherlands. mail@dvanderheijde.nl 
 
Laure Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis 
d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière 
Hospital, Department of rheumatology, Paris, France  




Sofia Ramiro, MD, PhD 
Department of Rheumatology 
Leiden University Medical Center 
PO Box 9600, Leiden 
The Netherlands 
E-mail: sofiaramiro@gmail.com 







We thank Tillet et. al for their comments[1] on our letter to the editor entitled ‘How are 
enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of 
psoriatic arthritis? A systematic literature review’.[2] We appreciate that the authors are in 
agreement with our view regarding the clear need for the harmonisation of outcome 
assessment in PsA.[1,2] We are aware of the work in this regard from the GRAPPA-
OMERACT initiative[3], as cited in our letter[2], which has indeed already led to an update of 
the Core Set of domains for PsA. Hopefully the next step that needs to be taken, namely the 
development of a Core Set of Outcome Measurements, will represent an important advance 
in standardization. Being an OMERACT initiative, it will implicitly need to follow the 
OMERACT filter,[4] which means that ‘For applicability, each instrument must prove to be 
truthful (valid), discriminative, and feasible’. For this we would like to highlight that feasibility 
is an important aspect that deserves appropriate attention, as otherwise the desired 
harmonization of outcome measurement will not be achieved, even if the instrument may 
have good psychometric properties. We further hope that the GRAPPA-OMERACT initiative 
takes all the issues addressed in our letter, but also the various aspects of instrument 
development discussed during the generation of the updated treat-to-target 
recommendations for axial and peripheral spondyloarthritis into account when proposing the 
Core Outcome Measurement Set.[2,5] We look forward to the updated Core Set and 
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